

Response to reviewers

Reviewer number 1

Specific Comments to Authors: There are two (C) but without (F) in Figure legends of Figure 1, please amend it.

Response: Letters in figure legends were amended

Reviewer number 2

I think that the manuscript would be more useful to readers who need to consider liver biopsy as part of the diagnostic work-up, if a flow chart was added that showed the role of liver biopsy

Response: A flow chart (Figure 2) describing an algorithm of the role of liver biopsy has been added to the manuscript

In addition the authors refer to grade III hepatitis and I think they should clearly define the oncological definitions of the grading of hepatitis.

Response: This is now defined in the paper, i.e. "which is $>5 \times \text{ULN}$ - $20 \times \text{ULN}$ and bilirubin $>3 \times \text{ULN}$ "

Lastly, I think it would be useful to discuss the subject of retreating patients who have checkpoint-inhibitor DILI with another checkpoint inhibitor and if liver biopsy could assist this decision.

Response: Unfortunately, it is unclear if a liver biopsy is helpful in the decision if another Check point inhibitor can be tried if hepatotoxicity has occurred with the first line Check point inhibitor.